Mechanism of Action and Vascular Effects
The cellular mechanism of action of calcium channel antagonists involves blocking voltage-gated calcium channels. This prevents $Ca^{2+}$ ions from entering target cells.
The hemodynamic cascade involves sequential steps:
- Decrease in intracellular calcium ion ($Ca^{2+}$) concentration.
- Reduction in the tone of vascular smooth muscle walls.
- Decrease in total peripheral resistance (TPR).
- Reduction in blood pressure (BP).
Pharmacological Profile of Amlodipine
Amlodipinum is characterized by a slow onset of pharmacological response and prolonged elimination.
Kinetic Parameters:
- Absorption: High oral bioavailability (64–80%).
- Peak concentration ($C_{max}$): Reached in 6–12 hours.
- Steady-state concentration: Formed by days 7–8 of administration.
- Elimination: A prolonged $t_{1/2}$ (35–50 hours) permits dosing once daily. It is metabolized by the liver into inactive products and excreted primarily by the kidneys.
Clinical Profile:
Amlodipinum is used for the systematic treatment of arterial hypertension and angina pectoris. Analogous drugs with a similar pharmacological profile include felodipine and lacidipine.
Reported adverse reactions include ankle edema, reflex tachycardia, headache, nausea, drowsiness, and dizziness.
Clinical Application of Nifedipine
Nifedipinum is characterized by a rapid and short-duration action (6 to 8 hours). The tactics of its administration depend on the formulation.
| Dosage Form | Route of Administration | Onset of Effect | Indications | Dosing Regimen |
|---|---|---|---|---|
| Short-acting (Corinfar, Phenigidine) | Sublingual | 15 minutes | Management of hypertensive crises | As needed |
| Extended-release (retard formulations, Adalat SL) | Oral | Gradual release | Systematic treatment of hypertension | Twice daily |
For routine long-term treatment of hypertension, only extended-release retard formulations are prescribed.